Download Sample
Add to CartBrucellosis Market
By Species;
Brucella Suis, Brucella Abortus, Brucella Melitensis, and Brucella CanisBy Diagnosis;
Serological Tests, Molecular Techniques, Bone Marrow Biopsy, X-Rays, Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), Cerebrospinal Fluid Culture, Echocardiography, and OthersBy Treatment;
Antibiotics, Vaccines, and OthersBy End-Use;
Hospitals & Diagnostic Centers, Academic Institutes, Pharmaceutical & Biotechnology Companies, and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).Brucellosis Market Overview
Brucellosis Market (USD Million)
Brucellosis Market was valued at USD 4,838.43 million in the year 2024. The size of this market is expected to increase to USD 6,324.32 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 3.9%.
Brucellosis Market
*Market size in USD million
CAGR 3.9 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 3.9 % |
| Market Size (2024) | USD 4,838.43 Million |
| Market Size (2031) | USD 6,324.32 Million |
| Market Concentration | High |
| Report Pages | 384 |
Major Players
- Hester Biosciences Limited
- ATA FEN Inc
- Biognesis-Bag S.A
- Biopharma
- Biovet
- Calier & Biologicos Laverlam
- Merck Animal Health
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Brucellosis Market
Fragmented - Highly competitive market without dominant players
The brucellosis market is expanding rapidly, driven by the rising prevalence of this zoonotic disease impacting both humans and animals. Nearly 12% to 15% of livestock worldwide are affected, creating a strong demand for effective diagnostics and treatments. Growing awareness of zoonotic infections and supportive health initiatives are fueling innovation, making this market a critical focus for public health and veterinary sectors.
Advances in Diagnostics and TreatmentOne of the major challenges is that nearly 18% of cases remain undetected due to limited diagnostic accuracy. This gap is pushing the adoption of molecular diagnostics and point-of-care testing, which ensure faster and more reliable detection. The demand for innovative treatments is also increasing, with a focus on antibiotic regimens and supportive therapies to improve disease outcomes.
Preventive Strategies Boosting Market GrowthVaccination campaigns now cover around 40% of livestock in regions where brucellosis remains a concern. These preventive measures, along with surveillance systems and biosecurity practices, are helping reduce transmission and economic losses. Preventive healthcare is thus emerging as a cornerstone for market growth, strengthening both human health and livestock productivity.
R&D and Innovation TrendsAround 22% of zoonotic disease research funding is currently dedicated to brucellosis and related infections. This investment is driving progress in next-generation vaccines, digital disease monitoring platforms, and improved therapeutic approaches. The integration of modern technologies is reshaping the market landscape and setting new standards in disease management.
Global Brucellosis Market Recent Developments
- In September 2023, The Department of Animal Husbandry and Veterinary Services, Panaji, Goa, implemented the Brucellosis Vaccination Programme under the National Animal Disease Control Programme. All cattle and female buffalo calves between the ages of 4 and 8 months underwent brucellosis vaccination.
- In April 2022, Ceva Santé Animale entered a joint venture with Mitsui & Co. Ltd to accelerate the expansion of the veterinary laboratory to Japan.
Brucellosis Market Segment Analysis
In this report, the Brucellosis Market has been segmented by Species, Diagnosis, Treatment, End-Use and Geography.
Brucellosis Market, Segmentation by Species
The Brucellosis Market has been segmented by Species into Brucella Suis, Brucella Abortus, Brucella Melitensis and Brucella Canis.
Brucella Suis
Brucella suis is a significant zoonotic pathogen, mainly found in swine but capable of infecting humans, particularly those in livestock handling and meat processing. Representing about 15% of global brucellosis cases, it demands strict biosecurity and targeted surveillance in farming communities
Brucella Abortus
Brucella abortus is the leading cause of bovine brucellosis, linked to nearly 40% of global infections. It is commonly transmitted to humans via raw or unpasteurized dairy products. Livestock vaccination campaigns and routine testing remain essential in reducing its prevalence
Brucella Melitensis
Brucella melitensis is recognized as the most virulent species, accounting for more than 35% of human brucellosis cases globally. Primarily associated with goats and sheep, it spreads through unpasteurized dairy and direct animal contact, making it a key focus of public health programs
Brucella Canis
Brucella canis primarily affects canines and contributes to roughly 10% of brucellosis cases. Human infections are rare but occur mainly among veterinary workers and kennel staff. Canine testing and strict breeding controls are crucial preventive measures
Brucellosis Market, Segmentation by Diagnosis
The Brucellosis Market has been segmented by Diagnosis into Serological Tests, Molecular Techniques, Bone Marrow Biopsy, X-Rays, Computerized Tomography (CT), Magnetic Resonance Imaging (MRI),, Cerebrospinal Fluid Culture, Echocardiography and Others.
Serological Tests
Serological testing is the most common method for identifying brucellosis, representing more than 45% of diagnoses globally. By detecting antibodies in the blood, these tests provide quick, sensitive results, making them highly effective for early detection
Molecular Techniques
Molecular methods, such as PCR, account for about 25% of confirmed cases and offer precise detection by targeting Brucella DNA. These techniques enable species identification, aiding in accurate treatment planning and timely intervention
Bone Marrow Biopsy
Bone marrow biopsy is applied in nearly 10% of cases, particularly for patients with prolonged fever or inconclusive serology. It remains a valuable confirmatory tool for chronic and complicated infections
X-Rays
X-rays, used in around 5% of cases, help identify skeletal complications like spondylitis and osteomyelitis. While not the primary method, they are important for evaluating structural damage caused by the disease.
Computerized Tomography (CT)
CT imaging contributes to approximately 4% of diagnoses, offering detailed visualization of internal organs. It is especially useful for detecting abscesses or neurological involvement in advanced cases.
Magnetic Resonance Imaging (MRI)
MRI is used in about 3% of cases and is particularly valuable for detecting neurological and musculoskeletal complications. Its high-resolution imaging makes it indispensable in complex clinical scenarios.
Cerebrospinal Fluid Culture
Cerebrospinal fluid culture, performed in roughly 2% of cases, directly isolates Brucella in suspected neurobrucellosis, confirming infection in the central nervous system.
Echocardiography
Echocardiography, applied in about 2% of cases, plays a vital role in identifying brucella-related endocarditis, particularly in patients with heart valve abnormalities or cardiac symptoms.
Others
Other diagnostic approaches, comprising around 4% of cases, include emerging rapid detection kits, specialized imaging tools, and experimental biomarkers under clinical evaluation.
Brucellosis Market, Segmentation by Treatment
The Brucellosis Market has been segmented by Treatment into Antibiotics, Vaccines and Others.
Antibiotics
Antibiotic therapy is the cornerstone of brucellosis management, making up more than 70% of treatment protocols worldwide. Combination regimens, typically using doxycycline with rifampin or streptomycin, are favored to prevent relapse and ensure complete bacterial clearance.
Vaccines
Vaccination plays a critical role in about 20% of prevention strategies, especially in livestock to minimize human exposure. While human vaccines are still in development, widespread veterinary immunization programs have successfully reduced disease prevalence in high-risk areas.
Others
Other treatment methods, accounting for close to 10% of cases, involve supportive therapies, targeted surgical procedures, and emerging experimental approaches aimed at improving outcomes for complex or chronic infections.
Brucellosis Market, Segmentation by End-Use
The Brucellosis Market has been segmented by End-Use into Hospitals & Diagnostic Centers, Academic Institutes, Pharmaceutical & Biotechnology Companies and Others.
Hospitals & Diagnostic Centers
Hospitals & diagnostic centers dominate the brucellosis end-use segment with over 50% share, offering advanced diagnostic services, specialized treatment protocols, and long-term patient care. Their role is vital in timely detection and effective disease management
Academic Institutes
Academic institutes hold approximately 20% market share, contributing through in-depth research, laboratory studies, and clinical trials. Their work is essential for developing new therapeutic strategies and improving diagnostic accuracy
Pharmaceutical & Biotechnology Companies
Pharmaceutical & biotechnology companies account for nearly 20% of end-use demand, focusing on the creation of novel antibiotics, vaccines, and next-generation treatment solutions. Their R&D initiatives are crucial in combating brucellosis globally
Others
Other end-users, making up about 10% of the market, encompass public health bodies, veterinary organizations, and NGOs dedicated to brucellosis control, community education, and preventive measures
Brucellosis Market, Segmentation by Geography
In this report, the Brucellosis Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
Brucellosis Market Share (%), by Geographical Region
North America
North America dominates the brucellosis market with over 35% share, benefiting from advanced healthcare infrastructure, widespread disease awareness, and robust veterinary practices. The U.S. plays a central role through extensive surveillance and eradication efforts
Europe
Europe holds close to 25% of the market, strengthened by stringent health regulations, active government intervention, and comprehensive livestock monitoring. Southern European countries such as Spain and Italy report relatively higher case numbers
Asia Pacific
Asia Pacific accounts for roughly 20% of global revenue, driven by expanding livestock industries and growing investment in public health programs. However, rural regions face diagnostic accessibility issues, slowing complete disease control
Middle East and Africa
Middle East and Africa together comprise about 12% of the market, where brucellosis remains widespread. Gaps in veterinary infrastructure and limited funding contribute to continued high incidence rates
Latin America
Latin America contributes around 8% to the market, with ongoing vaccination campaigns in key countries like Brazil and Argentina. Despite progress, underdiagnosis and insufficient surveillance hinder full eradication
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Brucellosis Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Livestock Management Initiatives
- Rising Awareness Programs
- Diagnostic Advancements
-
Government Initiatives: Government initiatives play a pivotal role in addressing the global burden of brucellosis by implementing policies, programs, and funding mechanisms aimed at prevention, control, and management of the disease. Across various countries and regions, governments collaborate with public health agencies, veterinary authorities, and international organizations to develop comprehensive strategies that encompass surveillance, diagnosis, treatment, and prevention measures.
In many endemic regions, governments prioritize brucellosis control through vaccination programs targeting livestock populations. These initiatives aim to reduce the prevalence of Brucella infection among animals, thereby minimizing the risk of transmission to humans through contaminated dairy products and meat. Governments also enforce regulations and guidelines for animal movement, quarantine measures, and biosecurity protocols in agricultural settings to prevent the spread of brucellosis and mitigate economic losses in livestock production.
Overall, government initiatives are essential in fostering a coordinated approach to brucellosis control, leveraging multisectoral collaboration and community engagement to achieve sustainable public health goals. By prioritizing brucellosis as a significant health and economic concern, governments contribute to global efforts in disease surveillance, prevention, and treatment, ultimately safeguarding both human and animal health against the impacts of this zoonotic disease.
Restraints:
- Limited Diagnostic Access
- Antibiotic Resistance
- Underreporting Challenges
-
Regulatory Hurdles: Regulatory hurdles present significant challenges in the global effort to combat brucellosis, affecting various aspects from diagnostic testing to treatment strategies and vaccine development. These hurdles often stem from differing regulatory frameworks across countries and regions, which can delay or complicate the approval process for new diagnostic tools, therapeutic agents, or vaccines intended for brucellosis control.
One of the primary regulatory challenges in brucellosis management is the approval and standardization of diagnostic tests. Variations in regulatory requirements among countries can lead to delays in the introduction of new diagnostic technologies, hindering timely and accurate diagnosis of Brucella infection. Harmonization of regulatory guidelines and collaborative efforts between regulatory authorities and health agencies are crucial to streamline the approval process and ensure rapid deployment of effective diagnostic tools.
Similarly, regulatory hurdles impact the development and distribution of vaccines for brucellosis prevention in livestock and, potentially, in humans. Vaccine candidates must undergo rigorous testing to demonstrate safety, efficacy, and consistency before regulatory approval can be obtained for commercial use. Challenges such as funding constraints, complex approval pathways, and differing vaccine importation regulations in endemic regions can pose barriers to vaccine deployment, limiting the effectiveness of preventive measures against brucellosis.
Addressing regulatory hurdles requires coordinated efforts among stakeholders, including governments, regulatory agencies, researchers, and industry partners. Advocacy for streamlined regulatory pathways, international collaboration on vaccine standardization, and investment in research to meet regulatory requirements are essential to overcome these challenges and accelerate progress in brucellosis control. By fostering a supportive regulatory environment, stakeholders can enhance global preparedness and response capabilities to mitigate the impact of brucellosis on public health and agriculture worldwide.
Opportunities:
- Vaccine Development
- Emerging Markets Expansion
- Technological Innovations
-
Public-Private Partnerships: Public-private partnerships (PPPs) play a crucial role in addressing the complex challenges of brucellosis control and management by leveraging the strengths and resources of both sectors. These collaborations bring together government agencies, international organizations, private companies, non-governmental organizations (NGOs), and academic institutions to jointly develop and implement sustainable strategies for disease prevention, diagnosis, treatment, and research.
In the context of brucellosis, PPPs facilitate innovative approaches to tackle the disease burden effectively. Private sector entities, including pharmaceutical companies and diagnostic manufacturers, contribute expertise in research and development (R&D) to advance new diagnostic tools, therapeutic treatments, and vaccines. These partnerships enable accelerated innovation by combining industry knowledge with government funding and regulatory support to expedite the introduction of novel solutions to combat brucellosis.
Effective PPPs also promote sustainable development goals by addressing socio-economic impacts of brucellosis, such as reduced productivity in livestock, loss of income for farmers, and healthcare costs associated with human infections. By aligning public health objectives with private sector expertise and resources, these partnerships contribute to broader initiatives aimed at improving food security, promoting economic resilience, and achieving health equity in communities affected by brucellosis.
In conclusion, public-private partnerships are integral to advancing brucellosis control efforts through collaborative innovation, capacity building, and sustainable development initiatives. By fostering shared responsibility and leveraging complementary strengths, PPPs contribute to comprehensive approaches that enhance resilience against brucellosis and promote health security on a global scale.
Competitive Landscape Analysis
Key players in Global Brucellosis Market include:
- Hester Biosciences Limited
- ATA FEN Inc
- Biognesis-Bag S.A
- Biopharma
- Biovet
- Calier & Biologicos Laverlam
- Merck Animal Health
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Species
- Market Snapshot, By Diagnosis
- Market Snapshot, By Treatment
- Market Snapshot, By End-Use
- Market Snapshot, By Region
- Brucellosis Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Livestock Management Initiatives
- Rising Awareness Programs
- Diagnostic Advancements
- Government Initiatives
- Restraints
- Limited Diagnostic Access
- Antibiotic Resistance
- Underreporting Challenges
- Regulatory Hurdles
- Opportunities
- Vaccine Development
- Emerging Markets Expansion
- Technological Innovations
- Public-Private Partnerships
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Brucellosis Market, By Species, 2021 - 2031 (USD Million)
- Brucella Suis
- Brucella Abortus
- Brucella Melitensis
- Brucella Canis
- Brucellosis Market, By Diagnosis, 2021 - 2031 (USD Million)
- Serological Tests
- Molecular Techniques
- Bone Marrow Biopsy
- X-Rays
- Computerized Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Cerebrospinal Fluid Culture
- Echocardiography
- Others
- Brucellosis Market, By Treatment, 2021 - 2031 (USD Million)
- Antibiotics
- Vaccines
- Others
- Brucellosis Market, By End-Use, 2021 - 2031 (USD Million)
- Hospitals & Diagnostic Centers
- Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Others
- Brucellosis Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Brucellosis Market, By Species, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Hester Biosciences Limited
- ATA FEN Inc
- Biognesis-Bag S.A
- Biopharma
- Biovet
- Calier & Biologicos Laverlam
- Merck Animal Health
- Company Profiles
- Analyst Views
- Future Outlook of the Market